Blog
RSS FeedPosted by Michael Wonder on 23 Feb 2023
Vir Biotechnology announces positive final draft guidance on sotrovimab from the UK’s NICE
22 February 2023 - Final draft guidance based on cost effectiveness evaluation of sotrovimab. ...
Posted by Michael Wonder on 23 Feb 2023
Daratumumab in combination with lenalidomide and dexamethasone for the first-line treatment of patients with multiple myeloma when stem cell transplantation is unsuitable
22 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 22 Feb 2023
Ataluren for the treatment of patients with Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
22 February 2023 - This guidance updates and replaces NICE highly specialised technologies guidance HST3 on the use of ataluren for ...
Posted by Michael Wonder on 22 Feb 2023
Ixazomib citrate and lenalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
22 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access agreement ...
Posted by Michael Wonder on 21 Feb 2023
NICE recommends 3 treatments for COVID-19 in final draft guidance
21 February 2023 - Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and ...
Posted by Michael Wonder on 21 Feb 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of adults with PSMA positive hormone-relapsed metastatic prostate cancer after two or more therapies
21 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 21 Feb 2023
Rimegepant sulphate for the treatment or prevention of migraine
21 February 2023 - The Department of Health and Social Care has NICE to produce guidance on the use of rimegepant ...
Posted by Michael Wonder on 17 Feb 2023
High drug prices are not justified by industry’s spending on research and development
15 February 2023 - Aris Angelis and colleagues argue that by refocusing their spending drug companies could provide more innovative ...
Posted by Michael Wonder on 17 Feb 2023
Teclistamab for the treatment of patients with relapsed or refractory multiple myeloma after three or more therapies
16 February 2023 - Another new cancer medicine becomes an assessment non-starter. ...
Posted by Michael Wonder on 17 Feb 2023
Mitapivat sulphate for the treatment of patients with pyruvate kinase deficiency
16 February 2023 - NICE is unable to make a recommendation on the the use of mitapivat sulphate (Pyrukynd) for the ...
Posted by Michael Wonder on 16 Feb 2023
NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines
16 February 2023 - NICE has today issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 ...
Posted by Michael Wonder on 16 Feb 2023
Tixagevimab and cilgavimab for the the prevention of COVID-19 disease
16 February 2023 - The Department of Health and Social Care has NICE to produce guidance on the use of ...
Posted by Michael Wonder on 09 Feb 2023
Lorlatinib for the first-line treatment of patients with ALK positive advanced non-small-cell lung cancer
9 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Feb 2023
Dapagliflozin propanediol monohydrate for the treatment of patients with chronic heart failure with preserved or mildly reduced ejection fraction
8 February 2023 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 09 Feb 2023
Empagliflozin for the treatment of patients with chronic heart failure with preserved or mildly reduced ejection fraction
8 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...